Research programme: osteoarthritis therapeutics - Asklepios
Alternative Names: BNP-OALatest Information Update: 27 May 2021
At a glance
- Originator Asklepios BioPharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Osteoarthritis in USA (Parenteral)
- 14 Jan 2013 Research programme is available for licensing as of 25 Sep 2012. http://www.askbio.com/
- 25 Sep 2012 Early research in Osteoarthritis in USA (Parenteral)